⌕
Relay Therapeutics · RLAY · Nasdaq
Tenet 43 · Weak
Compare
$17.27−4.53%At closeTenet 43 · Weak
$17.27−0.82 (−4.53%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Relay Therapeutics (RLAY) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 40% below its peak, net margin −1800.6%. Worth your attention in FY25: Share count (+80.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲53.4%
15.4
FY21→FY25CAGR +50.1%/yr
Net income ($M)▲18.1%
−276.5
FY21→FY25CAGR —
Free cash flow ($M)▲6.1%
−235.9
FY21→FY25CAGR —
Diluted EPS▲31.8%
−1.61
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+80.4%

95.1mn → 171.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$410.0K

−79.7% YoY in FY25 · 2.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)15.4Revenue0.0COGS15.4Gross profit−261.4R&D−56.7SG&A−302.7Op income26.3Tax & other−276.5Net income

-1801¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -1800.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7829, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
10,349.015,355.010,007.025,546.01,381.03,029.0▲53.4%+50.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
10,349.015,355.010,007.025,546.01,381.03,029.0▲53.4%+50.1%
Research & development
279,599.0261,383.0319,089.0330,018.0246,355.0295,650.0▼18.1%−3.0%
Selling, general & admin
51,084.056,710.076,592.074,950.065,978.057,386.0▼26.0%−0.3%
Total operating expenses
330,683.0318,093.0382,475.0398,546.0300,656.0367,727.0▼16.8%−3.6%
Operating incomefeeds ROC rank
−320,290.0−302,738.0−372,468.0−373,000.0−299,275.0−364,698.0▲18.7%—
Other income, net
26,701.026,259.034,760.031,027.08,766.0826.0——
Pretax income
−293,589.0−276,479.0−337,708.0−341,973.0−290,509.0−363,872.0▲18.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−293,633.0−276,479.0−337,708.0−341,973.0−290,509.0−363,872.0▲18.1%—
Per share
Diluted EPSbuyback-sensitive
−1.50−1.61−2.36−2.79−2.59−3.82▲31.8%—
Diluted shares (mn)
219.16171.59142.87122.58112.2395.14▲20.1%+15.9%
Margins
Gross margin
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−3094.9%−1971.6%−3722.1%−1460.1%−21670.9%−12040.2%▲1750.5pp+10068.6pp
Net margin
−2837.3%−1800.6%−3374.7%−1338.7%−21036.1%−12012.9%▲1574.1pp+10212.4pp
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Relay Therapeutics' revenue last fiscal year?

Relay Therapeutics reported revenue of $15.4M in fiscal 2025, up 53.4% from fiscal 2024.

What was Relay Therapeutics' net income?

Relay Therapeutics reported net income of −$276.5M in fiscal 2025, a net margin of −1800.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.